false
0001553643
0001553643
2025-07-22
2025-07-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July
22, 2025
RELMADA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Nevada |
|
001-39082 |
|
45-5401931 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
2222 Ponce de Leon Blvd., Floor 3
Coral Gables, FL |
|
33134 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code (212) 547-9591
| |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol |
|
Name of exchange on which registered |
| Common stock, $0.001 par value per share |
|
RLMD |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
As previously disclosed, on January 21, 2025,
Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the
Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business days ended January 17, 2025, the
Company’s security did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter that in accordance with Nasdaq
Listing Rule 5810(c)(3)(A), the Company had a compliance period of 180 calendar days from the date of the notice (“Initial Compliance
Period”), and that it may regain compliance if the closing bid of the Company’s security is at least $1 for a minimum
of ten consecutive business days during the Initial Compliance Period, which ended on July 21, 2025.
On July 22, 2025, Nasdaq notified the Company
that it had approved the Company’s application to transfer its listing to the Nasdaq Capital Market. The Company’s securities
will be transferred to the Nasdaq Capital Market at the opening of business on July 24, 2025. Nasdaq also approved a 180-day extension,
or until January 19, 2026 (the “Compliance Period”), to regain compliance with the minimum bid price in accordance with Nasdaq
Listing Rule 5550(a)(2). To regain compliance, the Company’s common stock must maintain a closing bid price of at least $1.00 per
share for a minimum of 10 consecutive business days at any time prior to the expiration of the Compliance Period.
The Company intends to actively monitor the Company’s
bid price during the Compliance Period and intends to take all reasonable measures available to regain compliance with the requirements
for continued listing on the Nasdaq Capital Market. While the Company plans to make diligent efforts to maintain the listing of its common
stock on Nasdaq, there can be no assurance that the Company will be able to regain or maintain compliance with the applicable continued
listing standards set forth in the Nasdaq Listing Rules.
Forward-Looking Statements
Certain statements in this Current Report
on Form 8-K (the “Current Report”) are “forward-looking statements” that are subject to substantial risks and
uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this Current Report may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,”
“outlook,” “forecast” or other similar words and include, without limitation, statements regarding the Company’s
ability to regain compliance with the minimum bid price rule for the Nasdaq Capital Market; the Company’s intent to monitor its
bid price and intention to take all reasonable measures available to the Company to regain compliance with requirements for continued
listing on the Nasdaq Capital Market.
Forward-looking statements are based on the
Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could
cause actual results to differ include, but are not limited to, the Company’s ability to regain compliance with the minimum bid
price; and the other important factors outlined under the caption “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), the latest Form 10-Q filed with the, as such
factors may be updated from time to time in its other filings with the SEC. Although the Company believes that the expectations reflected
in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake
any obligation, to update or revise any forward-looking statement made in this Current Report on Form 8-K to reflect changes since the
date of this Current Report on Form 8-K, except as may be required by law.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: July 23, 2025 |
RELMADA THERAPEUTICS, INC. |
| |
|
|
| |
By: |
/s/ Sergio Traversa |
| |
Name: |
Sergio Traversa |
| |
Title: |
Chief Executive Officer |
